Tesofensine
Tesofensine
A serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) originally developed for Alzheimer's and Parkinson's, found to cause dramatic weight loss. Discontinued after Phase IIb.
Typical Cost
Not commercially available
Status
Research
Peptide Profile
Tesofensine
Mechanism of Action
Triple reuptake inhibitor increasing serotonin, norepinephrine, and dopamine. Dramatically suppresses appetite and increases energy expenditure.
Common Dosages
oral
0.25-1mg
Daily · Not established
Benefits
Dramatic weight loss (12-14%)
Strong appetite suppression
Increased energy
Side Effects
Discontinued due to side effects
Cardiovascular concerns
Psychiatric effects
Not available
Key Research
Tesofensine obesity trial
12-14% weight loss in Phase IIb, superior to available drugs
Regulatory Status
Discontinued after Phase IIb. Not FDA-approved. Some research chemical availability.
Contraindications
- ⚠All populations - discontinued
- ⚠Cardiovascular disease
- ⚠Psychiatric history
Not appropriate. GLP-1 medications are safer and FDA-approved alternatives.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.